Phenylephrine Shortage: What Providers and Prescribers Need to Know in 2026

Providers across primary care, urgent care, emergency medicine, and allergy practices are increasingly fielding questions from patients about phenylephrine. Why is it disappearing from pharmacy shelves? Is Sudafed PE still safe? What should I take instead? This guide provides a clinical summary of the phenylephrine situation in 2026 and actionable guidance for patient counseling.

The Clinical Background: Why Oral Phenylephrine Is Being Removed

Oral phenylephrine's pharmacokinetics have long been a subject of clinical concern. The drug is well-absorbed from the gastrointestinal tract but undergoes extensive first-pass metabolism in the intestinal wall, primarily via monoamine oxidase. Studies have demonstrated that only approximately 40% of an orally administered dose reaches the systemic circulation, and only about 3% is excreted unchanged. The resulting plasma concentrations at standard OTC doses (10 mg every 4 hours) appear insufficient to produce meaningful alpha-1 adrenergic receptor activation in nasal vasculature.

In September 2023, the FDA's Nonprescription Drug Advisory Committee reviewed updated clinical trial data and unanimously concluded that oral phenylephrine is not Generally Recognized As Safe and Effective (GRASE) as a nasal decongestant at currently marketed doses. Notably, higher doses did not confer benefit either. On November 7, 2024, the FDA issued a proposed administrative order to remove oral phenylephrine from OTC Monograph M012.

Key Clinical Points for Provider Awareness

• Efficacy ruling, not a safety ruling. The FDA explicitly confirmed that no safety signal was identified for oral phenylephrine at approved doses. Patients who have been taking it do not need to be concerned about harm — they may simply not have been getting meaningful decongestant benefit.
• Only the oral form is affected. Intranasal phenylephrine (Neo-Synephrine nasal spray) remains GRASE and effective. IV phenylephrine (Vazculep, Biorphen) used for vasopressor support in anesthesia and septic shock is approved under an NDA and is entirely unaffected by this ruling.
• Combination products. Many multi-symptom OTC products (NyQuil, DayQuil, Mucinex Fast-Max, Benadryl Allergy Plus Sinus) contain oral phenylephrine alongside other active ingredients. The FDA confirmed that removal of phenylephrine from these products does not affect the efficacy of the other ingredients. Patients using these products for other symptoms (fever, cough, antihistamine effect) should be reassured on this point.
• Variable pharmacy availability. While oral phenylephrine is not in a supply shortage, some major chains (notably CVS) have voluntarily removed single-ingredient oral PE products from shelves. Availability will continue to vary by location until the FDA's final order.

Evidence-Based Alternatives to Recommend to Patients

When counseling patients on alternatives to oral phenylephrine, consider the underlying cause of congestion and the patient's comorbidities:

Pseudoephedrine (Sudafed) — Oral Decongestant

Pseudoephedrine is the most effective oral decongestant available without a prescription and has robust clinical data supporting its use. It stimulates both alpha and beta adrenergic receptors, producing nasal vasoconstriction. Standard dosing is 60 mg every 4–6 hours (max 240 mg/day) or 120 mg extended-release every 12 hours.

Clinical considerations: Pseudoephedrine can cause clinically meaningful increases in blood pressure and heart rate. Use caution in patients with uncontrolled hypertension, ischemic heart disease, tachyarrhythmias, or hyperthyroidism. Also contraindicated in patients taking MAOIs. Available behind the pharmacy counter without a prescription; patients must show ID and comply with purchase limits.

Oxymetazoline (Afrin) or Intranasal Phenylephrine — Topical Decongestants

Both oxymetazoline and phenylephrine nasal sprays provide rapid, effective decongestant relief. Because they act locally, systemic cardiovascular effects are minimal compared to oral decongestants. This makes them preferable for patients with hypertension or cardiovascular disease who need short-term decongestant relief.

Key counseling point: Both should be limited to 3 consecutive days of use. Rhinitis medicamentosa (rebound congestion) is a significant concern with extended use and may present as treatment-resistant nasal congestion in patients using these products chronically.

Intranasal Corticosteroids — First-Line for Allergic Rhinitis

Intranasal corticosteroids (fluticasone, mometasone, budesonide, triamcinolone) are first-line therapy for allergic rhinitis per AAAAI and ACR guidelines. They reduce nasal inflammation and address multiple symptoms including congestion, rhinorrhea, and sneezing. Patients should be counseled to expect a lag of several days to reach full effect. OTC options include fluticasone propionate (Flonase), triamcinolone (Nasacort), and budesonide (Rhinocort).

Antihistamines — For Allergy-Driven Congestion

Second-generation antihistamines (loratadine, cetirizine, fexofenadine) can be useful when congestion is driven primarily by histamine-mediated inflammation. They are well-tolerated, have a favorable cardiovascular safety profile, and are appropriate for patients with hypertension or other conditions that make decongestants risky. Combined loratadine-pseudoephedrine (Claritin-D) or similar products remain available for patients needing both antihistamine and decongestant effects.

Patient Counseling Talking Points

Here's how to address the most common patient questions about phenylephrine:

• "Is Sudafed PE dangerous?" Reassure patients that oral phenylephrine is safe. The FDA's concern is that it likely provides no meaningful decongestant benefit — not that it causes harm.
• "Why is my NyQuil different now?" Explain that some manufacturers are reformulating combination products to remove phenylephrine. The other ingredients — acetaminophen, dextromethorphan, antihistamines — remain effective and unchanged.
• "What's the real Sudafed?" Direct patients to ask the pharmacist for pseudoephedrine (the original, effective Sudafed), which is kept behind the counter. They'll need to show ID.

How medfinder Supports Your Patients

For patients struggling to find specific medications at local pharmacies, medfinder is a service that calls pharmacies on behalf of patients to check which ones carry a medication in stock, then texts the patient the results. This can save patients significant time and frustration — particularly useful when directing patients to find pseudoephedrine or other alternatives. See our full guide for how to help your patients find phenylephrine in stock.